Jeffrey E Rubnitz

List of Publications by Year
in descending order

279	21,314	7568	11308
papers	citations	77 h-index	136 g-index

281	281	281	15023
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 2009, 360, 2730-2741.	27.0	1,059
2	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology, The, 2009, 10, 147-156.	10.7	850
3	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 955-959.	1.6	563
4	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet, The, 2007, 370, 240-250.	13.7	547
5	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, The, 2010, 11, 543-552.	10.7	514
6	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood, 2007, 109, 926-935.	1.4	413
7	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 2004, 104, 2690-2696.	1.4	412
8	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	1.4	406
9	Gene expression profiling of pediatric acute myelogenous leukemia. Blood, 2004, 104, 3679-3687.	1.4	404
10	Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, The, 1998, 351, 550-554.	13.7	402
11	High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, The, 1999, 354, 34-39.	13.7	390
12	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	1.4	383
13	The minimum amount of homology required for homologous recombination in mammalian cells.. Molecular and Cellular Biology, 1984, 4, 2253-2258.	2.3	280
14	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	1.6	277
15	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	1.6	275
16	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2007, 297, 1207.	7.4	261
17	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 2010, 24, 371-382.	7.2	248
18	Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 2002, 100, 52-58.	1.4	240

#	Article	IF	Citations
19	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	27.8	236
20	The genomic landscape of core-binding factor acute myeloid leukemias. Nature Genetics, 2016, 48, 1551-1556.	21.4	215
21	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	1.6	213
22	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	16.8	213
23	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758.	1.4	205
24	TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance.. Journal of Clinical Oncology, 1997, 15, 1150-1157.	1.6	198
25	Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 2001, 97, 3727-3732.	1.4	192
26	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 3625-3632.	1.6	188
27	Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia, 2000, 14, 2286-2294.	7.2	187
28	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Journal of Clinical Oncology, 2019, 37, 2246-2256.	1.6	186
29	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	183
30	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	1.4	180
31	Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia. Journal of Clinical Oncology, 2003, 21, 3084-3091.	1.6	180
32	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncology, The, 2015, 16, 465-474.	10.7	177
33	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 2012, 120, 468-472.	1.4	176
34	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 2302-2309.	1.6	173
35	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12944-12949.	7.1	172
36	Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 2002, 100, 2399-2402.	1.4	171

#	Article	IF	Citations
37	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	1.6	169
38	Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood, 2009, 113, 5083-5089.	1.4	159
39	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 2011, 118, 223-230.	1.4	157
40	Safety of Lumbar Puncture for Children With Acute Lymphoblastic Leukemia and Thrombocytopenia. JAMA - Journal of the American Medical Association, 2000, 284, 2222.	7.4	156
41	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 1525-1532.	1.6	155
42	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. JAMA - Journal of the American Medical Association, 2003, 290, 2001.	7.4	155
43	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. Journal of Clinical Oncology, 2011, 29, 3293-3300.	1.6	142
44	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)â€“rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood, 2010, 116, 2644-2650.	1.4	141
45	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia, 2017, 31, 333-339.	7.2	140
46	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery, 2021, 11, 1440-1453.	9.4	137
47	Risk Factors for Traumatic and Bloody Lumbar Puncture in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2002, 288, 2001.	7.4	136
48	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 818-818.	1.6	128
49	Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia, 2009, 23, 1406-1409.	7.2	128
50	Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia, 1998, 12, 1176-1181.	7.2	127
51	Death during induction therapy and first remission of acute leukemia in childhood. Cancer, 2004, 101, 1677-1684.	4.1	126
52	Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America, 2010, 24, 35-63.	2.2	123
53	Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology, 2003, 123, 243-252.	2.5	122
54	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 386-391.	1.6	122

#	Article	IF	Citations
55	Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Annals of Oncology, 2017, 28, 386-392.	1.2	115
56	A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia, 2014, 28, 2336-2343.	7.2	113
57	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia, 2012, 26, 265-270.	7.2	112
58	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. Journal of Clinical Oncology, 2012, 30, 2005-2012.	1.6	104
59	Recombination events after transient infection and stable integration of DNA into mouse cells.. Molecular and Cellular Biology, 1985, 5, 659-666.	2.3	102
60	Childhood Acute Lymphoblastic Leukemia With the MLL-ENL Fusion and t(11;19)(q23;p13.3) Translocation. Journal of Clinical Oncology, 1999, 17, 191-191.	1.6	102
61	Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia, 2001, 15, 891-897.	7.2	102
62	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1079-1109.	4.9	96
63	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2016, 34, 4094-4101.	1.6	93
64	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncology, The, 2020, 21, 551-560.	10.7	92
65	Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study. Blood, 1997, 89, 1143-1146.	1.4	91
66	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1998, 16, 3768-3773.	1.6	89
67	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood, 2006, 108, 3997-4002.	1.4	89
68	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer, 2008, 113, 376-382.	4.1	87
69	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITDâ€“Positive Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 5758-5768.	7.0	87
70	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. Blood, 2013, 122, 2704-2713.	1.4	86
71	Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia, 1997, 11, 1201-1206.	7.2	85
72	Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2006, 108, 3302-3304.	1.4	85

#	Article	IF	Citations
73	Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer, 2007, 109, 157-163.	4.1	85
74	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 2302-2309.	1.6	85
75	Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia, 1998, 12, 1764-1770.	7.2	84
76	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer, 2008, 113, 522-529.	4.1	83
77	Prognostic factors in infants with acute myeloid leukemia. Leukemia, 2000, 14, 684-687.	7.2	82
78	IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia, 2011, 25, 1570-1577.	7.2	80
79	How I treat pediatric acute myeloid leukemia. Blood, 2012, 119, 5980-5988.	1.4	80
80	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer, 2005, 103, 368-376.	4.1	79
81	Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 2186-2191.	1.6	79
82	Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia, 1999, 13, 19-21.	7.2	78
83	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood, 2009, 114, 3764-3768.	1.4	78
84	Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. JAMA Oncology, 2020, 6, 552.	7.1	77
85	Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 935-945.	2.5	76
86	Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia, 1998, 12, 675-681.	7.2	75
87	Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia, 2003, 17, 2090-2096.	7.2	75
88	Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-MÃ¼nster Study Group. Journal of Clinical Oncology, 2015, 33, 4247-4258.	1.6	75
89	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		74
90	Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia, 2002, 16, 2072-2077.	7.2	73

#	Article	IF	Citations
91	RelA Mutant Enterococcus faecium with Multiantibiotic Tolerance Arising in an Immunocompromised Host. MBio, 2017, 8, .	4.1	72
92	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5499-5510.	7.0	71
93	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71
94	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7936-7941.	1.6	70
95	Rapid assay for extrachromosomal homologous recombination in monkey cells.. Molecular and Cellular Biology, 1985, 5, 529-537.	2.3	69
96	Childhood acute myeloid leukaemia. British Journal of Haematology, 2012, 159, 259-276.	2.5	68
97	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood, 2012, 119, e67-e75.	1.4	66
98	Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 4217-4224.	1.6	65
99	Current Management of Childhood Acute Myeloid Leukemia. Paediatric Drugs, 2017, 19, 1-10.	3.1	64
100	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Current Opinion in Hematology, 2002, 9, 345-352.	2.5	61
101	Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia, 2004, 18, 1072-1077.	7.2	61
102	Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight, 2018, 3, .	5.0	60
103	Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer, 2001, 92, 1959-1966.	4.1	59
104	Molecular Genetics of Childhood Leukemias. Journal of Pediatric Hematology/Oncology, 1998, 20, 1-11.	0.6	58
105	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	1.4	58
106	Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicinâ€“Containing Chemotherapy. Clinical Cancer Research, 2013, 19, 1620-1627.	7.0	58
107	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer, 2014, 120, 1514-1519.	4.1	58
108	Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10338-10343.	7.1	57

#	Article	IF	Citations
109	Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer, 2012, 118, 5989-5996.	4.1	56
110	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. Journal of Clinical Oncology, 2015, 33, 610-615.	1.6	56
111	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia, 2020, 34, 735-745.	7.2	56
112	Extrachromosomal and chromosomal gene conversion in mammalian cells.. Molecular and Cellular Biology, 1986, 6, 1608-1614.	2.3	54
113	Acute Myeloid Leukemia. Pediatric Clinics of North America, 2008, 55, 21-51.	1.8	54
114	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics, 2012, 11, 921-929.	4.1	54
115	Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia, 2005, 19, 2125-2129.	7.2	53
116	Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia, 2009, 23, 1410-1416.	7.2	53
117	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer, 2014, 120, 1985-1992.	4.1	53
118	Impact of age on outcome of pediatric acute myeloid leukemia. Cancer, 2006, 106, 2495-2502.	4.1	52
119	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatric Blood and Cancer, 2006, 47, 931-935.	1.5	51
120	Genetic Variants in Cytosolic 5â€²-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 9-23.	2.5	50
121	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. Journal of the National Cancer Institute, 2011, 103, 893-905.	6.3	50
122	Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude experience. Pediatric Blood and Cancer, 2007, 48, 10-15.	1.5	46
123	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood, 2002, 100, 43-47.	1.4	45
124	Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6â€“RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genetics and Cytogenetics, 2006, 169, 50-57.	1.0	44
125	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 414-423.	4.9	44
126	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2002, 50, 419-428.	2.3	43

#	Article	IF	Citations
127	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treatment Reviews, 2003, 29, 31-44.	7.7	43
128	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular Cancer Therapeutics, 2008, 7, 1110-1120.	4.1	43
129	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infectious Diseases, The, 2018, 18, 854-863.	9.1	43
130	Minimal Residual Disease Quantitation in Acute Myeloid Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S281-S285.	1.4	42
131	Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood, 2013, 121, 4366-4376.	1.4	42
132	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer, 2013, 119, 4036-4043.	4.1	41
133	Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Childrenâ€™s Oncology Group Study POG 9421. Leukemia, 2013, 27, 731-734.	7.2	41
134	Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243.	2.3	41
135	Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia, 2009, 23, 245-250.	7.2	40
136	Ontogeny and Sorafenib Metabolism. Clinical Cancer Research, 2012, 18, 5788-5795.	7.0	40
137	Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clinical Pharmacology and Therapeutics, 2017, 101, 373-381.	4.7	40
138	How I treat pediatric acute myeloid leukemia. Blood, 2021, 138, 1009-1018.	1.4	40
139	Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation. Leukemia, 2005, 19, 1399-1403.	7.2	39
140	Natural killer cell therapy in children with relapsed leukemia. Pediatric Blood and Cancer, 2015, 62, 1468-1472.	1.5	39
141	Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia, 2016, 30, 1184-1187.	7.2	39
142	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. Journal of Clinical Investigation, 2017, 128, 369-380.	8.2	39
143	Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia. European Journal of Oncology Nursing, 2009, 13, 156-163.	2.1	38
144	Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 194-207.	5.0	38

#	Article	IF	Citations
145	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. Neoplasia, 1999, 1, 253-261.	5.3	37
146	Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia, 2009, 23, 402-404.	7.2	37
147	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology, 2013, 72, 369-378.	2.3	36
148	Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatric Blood and Cancer, 2005, 44, 63-69.	1.5	35
149	Second malignancy after treatment of childhood acute myeloid leukemia. Leukemia, 2001, 15, 41-45.	7.2	34
150	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica, 2014, 99, 299-307.	3.5	34
151	Decreased relapsed rate and treatmentâ€related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer, 2017, 123, 3791-3798.	4.1	34
152	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 2072-2081.	1.6	34
153	Cutaneous Infection Caused by Macrophomina phaseolina in a Child with Acute Myeloid Leukemia. Journal of Clinical Microbiology, 2009, 47, 1969-1972.	3.9	32
154	Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer, 2012, 118, 6253-6259.	4.1	32
155	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. British Journal of Haematology, 2015, 168, 94-101.	2.5	31
156	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985.	12.8	31
157	Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia, 2001, 15, 1326-1330.	7.2	30
158	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer, 2016, 63, 1546-1551.	1.5	29
159	Childhood Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2008, 9, 95-105.	3.0	27
160	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics, 2011, 12, 327-339.	1.3	27
161	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer, 2013, 119, 2061-2066.	4.1	27
162	RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics, 2013, 14, 1449-1466.	1.3	27

#	Article	IF	Citations
163	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clinical Pharmacology and Therapeutics, 2016, 99, 651-660.	4.7	27
164	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	12.8	26
165	Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. Oncotarget, 2018, 9, 26711-26723.	1.8	26
166	Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia, 2003, 17, 541-546.	7.2	25
167	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer, 2010, 116, 98-105.	4.1	24
168	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2019, 134, 285-285.	1.4	24
169	Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia, 2004, 18, 1581-1586.	7.2	23
170	Voriconazole Prophylaxis in Children With Cancer. Pediatric Infectious Disease Journal, 2013, 32, e451-e455.	2.0	23
171	Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2002, 24, 561-565.	0.6	22
172	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2013, 60, 1161-1164.	1.5	22
173	Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. Leukemia Research, 2011, 35, 1321-1329.	0.8	21
174	Bone mineral density in children with acute lymphoblastic leukemia. Cancer, 2018, 124, 1025-1035.	4.1	21
175	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discovery, 2021, 2, 586-599.	5.0	21
176	Childhood Acute Lymphoblastic Leukemia. Oncologist, 1997, 2, 374-380.	3.7	21
177	Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2005, 44, 138-141.	1.5	20
178	Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Current Opinion in Hematology, 1997, 4, 233-241.	2.5	19
179	Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leukemia Research, 2004, 28, 349-352.	0.8	19
180	Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia, 2011, 25, 1354-1356.	7.2	19

#	Article	IF	Citations
181	Molecular diagnostics in the treatment of leukemia. Current Opinion in Hematology, 1999, 6, 229.	2.5	18
182	New approaches for the immunotherapy of acute myeloid leukemia. Discovery Medicine, 2015, 19, 275-84.	0.5	18
183	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	1.5	17
184	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology, 2012, 156, 275-279.	2.5	16
185	Concurrent translocations ofMLL andCBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 28, 227-232.	2.8	15
186	PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics, 2009, 25, 2013-2019.	4.1	15
187	Acute Megakaryoblastic Leukemia Without GATA1 Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. Journal of Clinical Oncology, 2011, 29, e230-e233.	1.6	15
188	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research, 2019, 25, 7320-7330.	7.0	14
189	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	1.4	14
190	Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. European Journal of Paediatric Neurology, 2010, 14, 78-79.	1.6	13
191	Randomized trial of 2 dosages of prophylactic granulocyteâ€“colonyâ€stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. Cancer, 2011, 117, 1313-1320.	4.1	13
192	Vancomycin Heteroresistance and Clinical Outcomes in Bloodstream Infections Caused by Coagulase-Negative Staphylococci. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
193	Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?. Expert Review of Hematology, 2014, 7, 427-429.	2.2	12
194	Definition of cure in childhood acute myeloid leukemia. Cancer, 2014, 120, 2490-2496.	4.1	12
195	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3â€ITD AML. Clinical and Translational Science, 2019, 12, 641-647.	3.1	12
196	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	4.1	12
197	Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML. Oncotarget, 2018, 9, 34859-34875.	1.8	12
198	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	4.1	11

#	Article	IF	Citations
199	Correction of deletions in mammalian cells by gene conversion. Somatic Cell and Molecular Genetics, 1987, 13, 183-190.	0.7	10
200	Lack of ETV6 (TEL) gene rearrangements or p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Leukemia, 1997, 11, 979-983.	7.2	10
201	Significance of the TEL-AML1 fusion gene in childhood AML. Leukemia, 1999, 13, 1470-1471.	7.2	10
202	Baseline mannose binding lectin levels may not predict infection among children with leukemia. Pediatric Blood and Cancer, 2008, 50, 866-868.	1.5	10
203	Spinal epidural lipomatosis in children with hematologic malignancies. Annals of Hematology, 2011, 90, 1067-1074.	1.8	10
204	Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. Leukemia, 2021, 35, 2258-2273.	7.2	10
205	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood Advances, 2022, 6, 521-527.	5.2	10
206	Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study. PLoS ONE, 2015, 10, e0135904.	2.5	9
207	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal, 2019, 19, 305-314.	2.0	9
208	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. Leukemia, 2022, 36, 1951-1960.	7.2	9
209	Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. Blood, 2014, 124, 972-972.	1.4	8
210	Clinical significance ofin vivocytarabine-induced gene expression signature in AML. Leukemia and Lymphoma, 2016, 57, 909-920.	1.3	7
211	Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics, 2018, 19, 1101-1110.	1.3	7
212	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital â€“ Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 757-757.	1.4	7
213	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. Journal of Clinical Oncology, 2022, 40, 772-783.	1.6	7
214	Isolated Nasal Septum Necrosis Caused by Aspergillus flavus in an Immunocompromised Child. Pediatric Infectious Disease Journal, 2011, 30, 627-629.	2.0	6
215	Global Proteomic Profiling of Pediatric AML: A Pilot Study. Cancers, 2021, 13, 3161.	3.7	6
216	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	6

#	Article	IF	Citations
217	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 2021, 4, e2128385.	5.9	6
218	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leukemia and Lymphoma, 2017, 58, 247-250.	1.3	5
219	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
220	DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. Cancers, 2020, 12, 3024.	3.7	5
221	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	5
222	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2018, 132, 3966-3966.	1.4	5
223	Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients. Blood, 2018, 132, 1536-1536.	1.4	5
224	Constitutive behavior of methionyl-tRNA synthetase compared to repressible behavior of methionine adenosyltransferase in mammalian cells. Biochimica Et Biophysica Acta - General Subjects, 1981, 677, 269-273.	2.4	4
225	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. Pediatric Blood and Cancer, 2008, 50, 542-548.	1.5	4
226	Somatic recombination of themnd chromosomal region in diploids and dikaryons ofSchizophyllum commune. Experimental Mycology, 1985, 9, 122-132.	1.6	3
227	BCL6 rearrangement and mediastinal involvement in a case of B cell acute lymphoblastic leukemia. Leukemia, 1998, 12, 1163-1165.	7.2	3
228	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. Pediatric Blood and Cancer, 2017, 64, e26632.	1.5	3
229	Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study. Blood, 2018, 132, 655-655.	1.4	3
230	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. Blood, 2020, 136, 23-24.	1.4	3
231	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. Blood, 2010, 116, 1073-1073.	1.4	3
232	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. Blood, 2015, 126, 4872-4872.	1.4	3
233	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, 10004-10004.	1.6	3
234	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. Blood, 2009, 114, 114-114.	1.4	3

#	Article	IF	Citations
235	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Advances, 2022, 6, 2824-2834.	5.2	3
236	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clinical Cancer Research, 2022, 28, 2536-2546.	7.0	3
237	Acute myeloid leukemia. , 2006, , 499-539.		2
238	Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection. Clinical Chemistry, 2020, 66, 518-522.	3.2	2
239	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2020, 136, 12-13.	1.4	2
240	An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Childrenâ€™s Oncology Group Protocols AAML0531 and 03P1 and St Jude Childrenâ€™s Research Hospital Protocol AML02. Blood, 2014, 124, 277-277.	1.4	2
241	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML. Blood, 2015, 126, 1345-1345.	1.4	2
242	Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 4474-4474.	1.4	2
243	Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML. Blood, 2018, 132, 2758-2758.	1.4	2
244	MRD in AML: it's time to face the FACS. Blood, 2003, 101, 3341-3341.	1.4	1
245	Acute myeloid leukemia. , 0, , 395-420.		1
246	POST: A framework for set-based association analysis in high-dimensional data. Methods, 2018, 145, 76-81.	3.8	1
247	Acute Myeloid Leukemia in Children. , 2018, , 981-993.		1
248	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. Blood, 2019, 134, 918-918.	1.4	1
249	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. Blood, 2020, 136, 26-27.	1.4	1
250	Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis. Blood, 1999, 93, 315-320.	1.4	1
251	Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2018, 36, TPS10575-TPS10575.	1.6	1
252	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. Blood, 2010, 116, 495-495.	1.4	1

#	Article	IF	Citations
253	The methylome of pediatric acute myeloid leukemia.. Journal of Clinical Oncology, 2015, 33, 10027-10027.	1.6	1
254	Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts. Blood, 2018, 132, 290-290.	1.4	1
255	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. Blood, 2019, 134, 379-379.	1.4	1
256	A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. Blood, 2019, 134, 1429-1429.	1.4	1
257	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3406-3406.	1.4	1
258	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
259	POST: A framework for set-based association analysis in high-dimensional data. , 2017, , .		0
260	Activity of venetoclax against relapsed acute undifferentiated leukemia. Cancer, 2021, 127, 2608-2611.	4.1	0
261	Minimal Residual Diseaseâ€“Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. Blood, 2009, 114, 16-16.	1.4	0
262	5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.. Blood, 2009, 114, 593-593.	1.4	0
263	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	1.4	0
264	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. Blood, 2010, 116, 849-849.	1.4	0
265	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Muˆnster AML Study Group.. Blood, 2012, 120, 2516-2516.	1.4	0
266	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	1.4	0
267	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	1.4	0
268	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. Blood, 2014, 124, 481-481.	1.4	0
269	Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2434-2434.	1.4	0
270	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	1.4	0

#	Article	IF	Citations
271	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. Blood, 2016, 128, 2838-2838.	1.4	0
272	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
273	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 178-178.	1.4	0
274	Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 28, 227-232.	2.8	0
275	Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML. Blood, 2021, 138, 3429-3429.	1.4	0
276	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. Blood, 2021, 138, 4415-4415.	1.4	0
277	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. Blood, 2021, 138, 2295-2295.	1.4	0
278	Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. Blood, 2021, 138, LBA-4-LBA-4.	1.4	0
279	78. Non-Invasive Prediction of Invasive Fungal Infection by Plasma-Based Microbial Cell-Free DNA Next-Generation Sequencing (mcfDNA NGS) in Pediatric Patients with Relapsed or Refractory Leukemia. Open Forum Infectious Diseases, 2021, 8, S51-S51.	0.9	0